Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006

Journal of Clinical Microbiology

Volumn 49, Issue 7, 2011, Pages 2404-2410

  Lockhart, Shawn R ^a   Wagner, Debra ^a   Iqbal, Naureen ^a   Pappas, Peter G ^b   Andes, David R ^c   Kauffman, Carol A ^d   Brumble, Lisa M ^e   Hadley, Susan ^f   Walker, Randall ^g   Ito, James I ^h   Baddley, John W ^b,i   Chiller, Tom ^a   Park, Benjamin J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e MAYO CLINIC   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g MAYO CLINIC   (United States)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁱ BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; GANCICLOVIR; ITRACONAZOLE; POSACONAZOLE; VIRUS ANTIGEN; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; FEMALE; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHODGKIN LYMPHOMA; NONHUMAN; ORGAN TRANSPLANTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; STEM CELL TRANSPLANTATION;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, INVASIVE; DRUG RESISTANCE, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS; ORGAN TRANSPLANTATION; STEM CELL TRANSPLANTATION; TRANSPLANTATION;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CYTOMEGALOVIRUS;

EID: 79959855170     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02474-10     Document Type: Article

References (34)

1. Abi-Said, D., et al. 1997. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24:1122-1128. (Pubitemid 127774267)
2. Ahlquist, A., et al. 2009. Epidemiology of candidemia in metropolitan Atlanta and Baltimore city and county: preliminary results of population-based active, laboratory surveillance-2008-2010, abst. M-1241. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
3. Alexander, B. D., W. A. Schell, J. L. Miller, G. D. Long, and J. R. Perfect. 2005. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 80:868-871.
4. Ascioglu, S., et al. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34:7-14.
5. Bhatti, Z., A. Shaukat, N. G. Almyroudis, and B. H. Segal. 2006. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia 162:1-15.
6. Clinical and Laboratory Standards Institute. 2008. M27-S3 reference method for broth dilution antifungal susceptibility testing of yeasts, third informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Courtney, R., S. Pai, M. Laughlin, J. Lim, and V. Batra. 2003. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 47:2788-2795.
8. Goodman, J. L., et al. 1992. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326:845-851.
9. Hajjeh, R. A., et al. 2004. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42:1519-1527.
10. Hope, W., A. Morton, and D. P. Eisen. 2002. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J. Hosp. Infect. 50:56-65.
11. Iwen, P. C., D. M. Kelly, E. C. Reed, and S. H. Hinrichs. 1995. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin. Infect. Dis. 20:342-347.
12. Kao, A. S., et al. 1999. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin. Infect. Dis. 29:1164-1170.
13. Kontoyiannis, D. P., et al. 2010. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin. Infect. Dis. 50:1091-1100.
14. Kunova, A., et al. 1997. Eight-year surveillance of non-albicans Candida spp. in an oncology department prior to and after fluconazole had been introduced into antifungal prophylaxis. Microb. Drug Resist. 3:283-287.
15. Linton, C. J., et al. 2007. Molecular identification of unusual pathogenic yeast isolates by large ribosomal subunit gene sequencing: 2 years of experience at the United Kingdom mycology reference laboratory. J. Clin. Microbiol. 45:1152-1158.
16. Mann, P. A., et al. 2009. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob. Agents Chemother. 53:5026-5034.
17. Marr, K. A., K. Seidel, T. C. White, and R. A. Bowden. 2000. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis. 181:309-316.
18. National Committee for Clinical Laboratory Standards. 2002. M27-A2 reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard, 2nd ed. National Committee for Clinical Laboratory Standards, Wayne, PA.
19. Neofytos, D., et al. 2009. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin. Infect. Dis. 48:265-273.
20. Pappas, P. G., et al. 2010. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 50:1101-1111.
21. Pfaller, M. A., et al. 2007. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 45:1735-1745.
22. Pfaller, M. A., et al. 2010. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J. Clin. Microbiol. 48:1366-1377.
23. Pfaller, M. A., et al. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46:2620-2629.
24. Pfaller, M. A., et al. 2008. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J. Clin. Microbiol. 46:515-521.
25. Pfaller, M. A., et al. 2009. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J. Clin. Microbiol. 47:3185-3190.
26. Safdar, A., F. van Rhee, J. P. Henslee-Downey, S. Singhal, and J. Mehta. 2001. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transpl. 28:873-878.
27. Sanglard, D., and F. C. Odds. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2:73-85.
28. Silveira, F. P., and S. Husain. 2007. Fungal infections in solid organ transplantation. Med. Mycol. 45:305-320.
29. Slavin, M. A., et al. 2010. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J. Antimicrob. Chemother. 65:1042-1051.
30. Trick, W. E., S. K. Fridkin, J. R. Edwards, R. A. Hajjeh, R. P. Gaynes, and National Nosocomial Infections Surveillance System Hospitals. 2002. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. 35:627-630.
31. Trifilio, S., et al. 2007. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transpl. 40:451-466.
32. White, M. H. 1997. The contribution of fluconazole to the changing epidemiology of invasive candidal infections. Clin. Infect. Dis. 24:1129-1130.
33. Wingard, J. R., et al. 1993. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. 37:1847-1849.
34. Wingard, J. R., et al. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325:1274-1277.